Evaluation of statin utilisation in tertiary care teaching hospital: An observational prospective study, YSR Kadapa-Reference-Cited by-同舟云学术

Evaluation of statin utilisation in tertiary care teaching hospital: An observational prospective study, YSR Kadapa

Published:2023-06-01 Issue:2 Volume:4 Page:26-33
ISSN:2582-7235
Container-title:Journal of Pharmacovigilance and Drug Research
language:
Short-container-title:jpadr

Author:

Uppicherla Suchitra,Tadimarri Divya Sree,K. N. Nandha Kumar,Rajaboyna Haritha,Yadavendra Reddy K. D.,Ponnolu Gowtham Kumar Reddy,Cuddapah Rajaram,B. Jeevan Kumar

Abstract

ABSTRACT; Introduction: Statins are highly preferred drugs in the treatment and prevention of atherosclerotic diseases. Statins usage increased in the last two decades. DUE is a cyclic quality-enhancing procedure in the prescription of drugs. Methods: Our study engaged in compiling various prescribing conditions for statins, assessing their effectiveness and safety, and comparing the lipid profile images of atorvastatin and rosuvastatin. A prospective observational study with the involvement of 150 volunteers The complete data collected is analysed using SAS and Microsoft Excel software. Statistical methods of mean, standard deviation, clinical significance, and Z value are calculated. Results: Atorvastatin (20 mg, 40 mg, and 80 mg) and Rosuvastatin (5 mg and 10mg) are widely used in the primary, secondary, and tertiary prevention of atherosclerotic cardiovascular and cerebrovascular problems. Average reduction of LDL and total cholesterol levels to 106.5(SD ±11.04) and 203.53 (SD±94) respectively. Key words: Atorvastatin, cardiovascular and cerebrovascular problems, non adherence, Re-occurrence, Rosuvastatin.

Publisher

Global Pharmacovigilance Society

Reference23 articles.

1. Al-Shura, A. N. (2014). Hematology in Traditional Chinese Medicine Cardiology. Elsevier.

2. Berne, C., Siewert-Delle, A. (2005). Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovascular Diabetology, 4(1), 1-11.

3. Bernini, F., Poli, A., Paoletti, R. (2001). Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. Cardiovascular drugs and therapy, 15, 211-218.

4. Chaiyakunapruk, N., Asuphol, O., Dhippayom, T., Poowaruttanawiwit, P., Jeanpeerapong, N. (2011). Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. International Journal of Pharmacy Practice, 19(2), 129-135.

5. Choudhry, N. K., Dugani, S., Shrank, W. H., Polinski, J. M., Stark, C. E., Gupta, R., Jha, P. (2014). Despite increased use and sales of statins in India, per capita prescription rates remain far below high-income countries. Health Affairs, 33(2), 273-282.